Aytu BioScience (AYTU) Stock Forecast & Price Target

Aytu BioPharma is viewed positively because its fiscal Q4 FY26 revenue of $16.1 million beat estimates by a wide margin and pro forma EPS of $0.03 also exceeded expectations, signaling improving operating execution. The company’s growth story is increasingly centered on EXXUA, which launched in Q4 2025 to an encouraging start and targets the $22 billion U.S. prescription MDD market, where more than 340 million antidepressant prescriptions were written in 2024 but side-effect concerns remain a major unmet need. With clinical data from more than 5,000 patients showing meaningful symptom relief and placebo-comparable rates of sexual side effects or weight gain, the stock’s attractive valuation appears to understate the upside if commercialization continues to gain traction.

Aytu BioPharma is facing a deteriorating fundamentals picture, as FY27 revenue estimates were cut to $68 million from $70 million and EPS was reduced to $(0.16) from $0.25, signaling weaker profitability than previously expected. Its fiscal Q3 FY26 results, reported on May 13, showed revenue of $12.4 million, down 33% year over year, while pro forma EPS of $(0.43) underscored continued losses and no Q3 guidance left little near-term visibility. The company also carries meaningful balance sheet and liquidity, regulatory, commercialization, reimbursement, and competitive risks, which, combined with shifting patient and physician demand, make execution highly uncertain.